Niapelf (Paliperidone)

Paliperidone, the active ingredient in Niapelf, is a atypical antipsychotic presented as a intramuscular injection for intramuscular use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adults. GNH USA supplies Niapelf as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is an atypical antipsychotic used in the management of psychotic disorders. - Schizophrenia: reduces positive and negative symptoms and helps maintain stability. - Schizoaffective disorder: controls both mood and psychotic features. - Maintenance therapy for schizophrenia: prevents relapse and reduces hospitalization risk.

Paliperidone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Weight gain: increase in body weight over treatment duration. - Akathisia: restlessness or an inability to stay still. - Somnolence: feeling unusually sleepy or fatigued. - Elevated prolactin: menstrual disturbances or galactorrhea. - Dizziness: transient light‑headedness, especially on standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever, rigidity, and autonomic instability. - Tardive dyskinesia: persistent involuntary movements, often of the face or tongue. - Seizures: increased risk in susceptible individuals. - Severe hypotension: marked drop in blood pressure causing fainting. - Agranulocytosis: dangerously low white‑blood‑cell count.

Before initiating therapy with Paliperidone, clinicians should consider several safety aspects. - Metabolic monitoring: regularly assess weight, glucose, and lipid levels. - Cardiovascular assessment: evaluate for history of arrhythmia or orthostatic hypotension. - Seizure risk: avoid in patients with uncontrolled epilepsy. - Prolactin effects: monitor for galactorrhea, menstrual changes, or sexual dysfunction. - Elderly patients with dementia: use with caution due to increased mortality risk. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase paliperidone plasma levels. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise exposure and risk of adverse effects. - Other dopamine antagonists (e.g., haloperidol): additive risk of extrapyramidal symptoms.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: may enhance orthostatic hypotension. - CNS depressants (e.g., benzodiazepines, opioids): increase sedation and dizziness.